APELLIS PHARMACEUTICALS INC (APLS) Stock Price, Quote, News and Overview
NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD
APLS Quote, Performance and Key Statistics
16.93
-0.48 (-2.76%)
The current stock price of APLS is 16.93 USD. In the past month the price decreased by -15.69%. In the past year, price decreased by -56.87%.
APLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 328.74B | ||
| AMGN | AMGEN INC | 13.88 | 154.96B | ||
| GILD | GILEAD SCIENCES INC | 14.22 | 136.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.06 | 52.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.71B | ||
| ARGX | ARGENX SE - ADR | 97.66 | 35.00B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.28 | 26.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.03B | ||
| NTRA | NATERA INC | N/A | 21.54B | ||
| BIIB | BIOGEN INC | 8.2 | 19.02B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.72 | 14.38B |
Related stock screener links
About APLS
Company Profile
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 705 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Company Info
APELLIS PHARMACEUTICALS INC
100 Fifth Avenue
Waltham MASSACHUSETTS 02451 US
CEO: Cedric Francois
Employees: 708
Phone: 16179775700
APELLIS PHARMACEUTICALS INC / APLS FAQ
What is the stock price of APELLIS PHARMACEUTICALS INC today?
The current stock price of APLS is 16.93 USD. The price decreased by -2.76% in the last trading session.
What is the ticker symbol for APELLIS PHARMACEUTICALS INC stock?
The exchange symbol of APELLIS PHARMACEUTICALS INC is APLS and it is listed on the Nasdaq exchange.
On which exchange is APLS stock listed?
APLS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for APELLIS PHARMACEUTICALS INC stock?
29 analysts have analysed APLS and the average price target is 42.84 USD. This implies a price increase of 153.04% is expected in the next year compared to the current price of 16.93. Check the APELLIS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is APELLIS PHARMACEUTICALS INC worth?
APELLIS PHARMACEUTICALS INC (APLS) has a market capitalization of 2.13B USD. This makes APLS a Mid Cap stock.
How many employees does APELLIS PHARMACEUTICALS INC have?
APELLIS PHARMACEUTICALS INC (APLS) currently has 708 employees.
What are the support and resistance levels for APELLIS PHARMACEUTICALS INC (APLS) stock?
APELLIS PHARMACEUTICALS INC (APLS) has a resistance level at 17.27. Check the full technical report for a detailed analysis of APLS support and resistance levels.
Is APELLIS PHARMACEUTICALS INC (APLS) expected to grow?
The Revenue of APELLIS PHARMACEUTICALS INC (APLS) is expected to grow by 1.42% in the next year. Check the estimates tab for more information on the APLS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy APELLIS PHARMACEUTICALS INC (APLS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APLS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APLS, evaluating the profitability, health, valuation and growth aspects
- APELLIS PHARMACEUTICALS INC (APLS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APELLIS PHARMACEUTICALS INC (APLS) Sales and EPS estimates to see what analysts future expectations are.
- APELLIS PHARMACEUTICALS INC (APLS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APELLIS PHARMACEUTICALS INC (APLS) Insider and Institutional Ownership to learn about the owners and their transactions.
- APELLIS PHARMACEUTICALS INC (APLS) Stock Chart to make your own analysis
- APELLIS PHARMACEUTICALS INC (APLS) Latest news and press-releases to stay up to date.
Does APELLIS PHARMACEUTICALS INC (APLS) stock pay dividends?
APLS does not pay a dividend.
When does APELLIS PHARMACEUTICALS INC (APLS) report earnings?
APELLIS PHARMACEUTICALS INC (APLS) will report earnings on 2025-07-30, before the market open.
What is the Price/Earnings (PE) ratio of APELLIS PHARMACEUTICALS INC (APLS)?
APELLIS PHARMACEUTICALS INC (APLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).
What is the Short Interest ratio of APELLIS PHARMACEUTICALS INC (APLS) stock?
The outstanding short interest for APELLIS PHARMACEUTICALS INC (APLS) is 26.71% of its float. Check the ownership tab for more information on the APLS short interest.
APLS Technical Analysis
APLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APLS. Both the profitability and financial health of APLS have multiple concerns.
APLS Financial Highlights
Over the last trailing twelve months APLS reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 47.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.71% | ||
| ROE | -136.21% | ||
| Debt/Equity | 2.76 |
APLS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 81% to APLS. The Buy consensus is the average rating of analysts ratings from 29 analysts.
For the next year, analysts expect an EPS growth of -33.94% and a revenue growth 1.42% for APLS